País: Canadá
Idioma: inglés
Fuente: Health Canada
ACETYLSALICYLIC ACID
PHARMASCIENCE INC
B01AC06
ACETYLSALICYLIC ACID
81MG
TABLET
ACETYLSALICYLIC ACID 81MG
ORAL
100/500
OTC
SALICYLATES
Active ingredient group (AIG) number: 0101169013; AHFS:
APPROVED
2006-07-19
1 PRODUCT MONOGRAPH PMS-ASA (Acetylsalicylic acid chewable tablets, USP) 81 mg PRAXIS ASA EC 81 MG DAILY LOW DOSE (Acetylsalicylic acid delayed-release tablets, USP) 81 mg Platelet aggregation inhibitor Pharmascience, Inc Date of Preparation: 6111 Royalmount Ave # 100 July 18, 2006 Montreal, Quebec Date of Revision: H4P 2T4 July 30, 2009 CONTROL NO . 131594 2 PRODUCT MONOGRAPH PMS-ASA (Acetylsalicylic acid chewable tablets, USP) 81 mg PRAXIS ASA EC 81 MG DAILY LOW DOSE (Acetylsalicylic acid delayed release tablets, USP) 81 mg THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION Platelet aggregation inhibitor. ACTION AND CLINICAL PHARMACOLOGY ASA interferes with the production of prostaglandins in various organs and tissues through acetylation of the enzyme cyclo-oxygenase. Prostaglandins are themselves powerful irritants and produce headaches and pain on injection in man. Prostaglandins also appear to sensitize pain receptors to other noxious substances such as histamine and bradykinin. By preventing the synthesis and release of prostaglandins in inflammation, ASA may avert the sensitization of pain receptors. The antipyretic activity of ASA is due to its ability to interfere with the production of prostaglandin E 1 in the brain. Prostaglandin E 1 is one of the most powerful pyretic agents known. The inhibition of platelet aggregation by ASA is due to its ability to interfere with the production of thromboxane A 2 within the platelet. Thromboxane A 2 is largely responsible for the aggregating properties of platelets. 3 INDICATIONS AND CLINICAL USE Acetylsalicylic acid (ASA) is indicated for the following uses, based on its platelet aggregation inhibitory properties: -For reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction. -For reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction; In addition, pms-ASA 81 mg and Praxis ASA EC 81 mg Daily Low Dose 81 mg are also indicated for the fol Leer el documento completo